One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates

F Rodeghiero; G C Castaman; T Chisesi; A De Rossi; O Dalla Gassa; A Del Mistro; E Dini; S Castronovo; E Pornaro; L Chieco-Bianchi

doi:10.1055/s-0038-1660093

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1985; 54(03): 665-668
DOI: 10.1055/s-0038-1660093

Original Article

Schattauer GmbH Stuttgart

One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates

F Rodeghiero

¹The Department of Haematology, Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy

,

G C Castaman

¹The Department of Haematology, Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy

,

T Chisesi

¹The Department of Haematology, Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy

,

A De Rossi

²The Chair of Oncology, University of Padova, Italy

,

O Dalla Gassa

²The Chair of Oncology, University of Padova, Italy

,

A Del Mistro

²The Chair of Oncology, University of Padova, Italy

,

E Dini

¹The Department of Haematology, Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy

,

S Castronovo

¹The Department of Haematology, Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy

,

E Pornaro

³The Blood Transfusion Centre, Hospital of Padova, Italy

,

L Chieco-Bianchi

²The Chair of Oncology, University of Padova, Italy

› Author Affiliations

Abstract

PDF Download

Summary

A 1-year follow-up study of the T-cell subset abnormalities was carried out in 16 severe haemophilia A patients, treated “on demand” with an average amount of 500 U/kg/yr of factor VIII concentrate (group A) and in 15 mild haemophiliacs or von Willebrand patients treated only sporadically with less than 3000 U of factor VIII and no longer exposed to any other blood component in the 2 years preceding the beginning of the study (group B).

In group A, 50% and 70% of patients showed a reduced or inverted T 4/T 8 ratio, respectively, at the beginning and at the end of follow-up. These values were of 30% and 20% in patients of group B, suggesting a long-lasting effect of concentrate therapy on T-cell subsets. The low T 4/T 8 ratio was mainly due to an increase of suppressor cells. None of the patients was found positive for anti HTLV-I, whereas 3 patients, all belonging to the group A, showed antibodies against HTLV-III. Thus, in these patients, HTLV-III seems not to be the only cause of low T 4/T 8 ratio.

Keywords

Haemophilia - Commercial clotting factor concentrates - Acquired immunodeficiency syndrome - Immunological abnormalities in haemophilia - HTLV-I - HTLV-III

PDF (310 kb)

References

References
1 Jones P, Proctor S, Dickinson A, George S. Altered immmunology in haemophilia. Lancet 1983; 1: 213-214
2 Ledermann MM, Ratnoff OD, Scillian JJ, Jones PK, Schächter B. Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med 1983; 308: 79-83
3 Luban NL C, Kelleher JF. Altered distribution of T-lymphocyte subpopulation in children and adolescent with haemophilia. Lancet 1983; 1: 503
4 Lechner K, Niessner H, Bettelheim P, Deutsch E, Fasching I, Fuhrmann M, Hinterberger W, Korninger C, Neumann E, Liszka K, Knapp W, Mayr WR, Stingl G, Zeitlhuber U. T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates. Thromb Haemostas 1983; 50: 552-556
5 Goldsmith JC, Moseley PL, Monick M, Brady M, Hunninghake GW. T-lymphocyte subpopulation abnormalities in apparently healthy patients with haemophilia A. Ann Intern Med 1983; 98: 294-296
6 Waterson AP. Acquired immune deficiency syndrome. Br Med J 1983; 286: 743-746
7 Gottlieb MS, Groopman JE, Weinstein WM, Fahey JL, Detels R. The acquired immune deficiency syndrome. Ann Intern Med 1983; 99: 208-220
8 Broder S, Gallo RC. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med 1984; 311: 1292-1297
9 Seligmann M, Chess L, Fahey JL, Fauci AS, Lachmann PJ, L-’AgeStehr J, Ngu J, Pinching AJ, Rosen FS, Spira TJ, Wybran J. AIDS-An immunologic reevaluation. N Engl J Med 1984; 311: 1286-1292
10 The Lancet. Blood transfusion, haemophilia and AIDS. Lancet 1984; 2: 1433-1435
11 Cheinsong-Popov RC, Weiss RA, Dalgleish A, Tedder RS, Shanson DC, Jeffries DJ, Ferns RB, Briggs EM, Weller IV D, Mitton S, Adler MW, Farthing C, Lawrence AG, Gazzard BG, Weber J, Harris JR W, Pinching AJ, Craske J, Barbara JA J. Prevalence of antibody to Human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet 1984; 2: 477-479
12 Ramsay RB, Palmer EL, Me Dougal JS, Kalyanaraman VS, Jackson DW, Chorba TL, Holman RC, Evatt BL. Antibody to lymph-adenopathy-associated virus in haemophiliacs with and without AIDS. Lancet 1984; 2: 397-398
13 Saxinger C, Gallo RC. Application of the indirect enzyme-linked immunosorbent assay microtest to the detection and surveillance of Human T cell leukemia-lymphoma virus. Lab Invest 1983; 49: 371-377
14 Sarngadharan MG, Popovic M, Bruch L, Schüpbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 1984; 224: 506-509
15 Mannucci PM, Gringeri A, Ammassari M, Mari D. Abnormalities of lymphocyte subsets are correlated with concentrate consumption in asymptomatic Italian haemophiliacs treated with concentrates made from American plasma. Am J Hematol 1984; 17: 167-176
16 San Miguel JF, Vincente V, Gonzales M, Caballero MD, Rodriguez C, Alberca I, Lopez Borrasca A. T-cell subpopulations in untreated and treated patients with hemophilia A and B. Blut 1983; 47: 311-313
17 Moffat EH, Bloom AL, Mortimer PP. HTLV-III antibody status and immunological abnormalities in haemophilic patients. Lancet 1985; 1: 935
18 Palmer EL, Ramsey RB, Feorino PF, Harrison AK, Cabradilla C, Francis DP, Man-Chiu Poon, Evatt BL. Human T-cell leukemia virus in lymphocytes of two haemophiliacs with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101: 293-297
19 Tedder RS, Shanson DC, Jeffries DJ, Cheingsong Popov R, Clapham P, Dalgleish A, Nagy K, Weiss RA. Low prevalence in the U. K. of HTLV-I and HTLV-III infection in subjects with AIDS, with extended lymphadenopathy, and at risk of AIDS. Lancet 1984; 2: 125-128
20 Menitove JE, Aster RH, Casper JT, Laner ST, Gottshall JL, Williams JE, Gill JC, Wheeler DV, Piaskowski V, Kirchner P, Montgomery RR. T-lymphocyte subpopulations in patients with classic haemophilia treated with cryoprecipitate and lyophilized concentrates. N Engl J Med 1983; 308: 84-86
21 Lee CA, Jarrony G, Ashley J, Kernoff PB A. Plasma fractionation methods and T-cell subsets in haemophilia. Lancet 1983; 2: 158-159
22 Gjerset GF, Martin PJ, Counts RB, Fast LD, Hansen JA. Immunologic status of haemophilia patients treated with cryoprecipitate or lyophilized concentrate. Blood 1984; 64: 715-720
23 Rasi VP O, Koinstinen JL K, Lohman CM, Silvennoinen OJ. Normal T-cell subset ratios in patients with severe haemophilia A treated with cryoprecipitate. Lancet 1984; 1: 461